Start Date
October 31, 2015
Primary Completion Date
September 30, 2018
Study Completion Date
September 30, 2018
cabotegravir
Cabotegravir 30 mg tablets are formulated as white to almost white oval-shaped coated tablets for oral administration. The cabotegravir LA is formulated as a sterile white to slightly coloured suspension containing 400mg/2mL of cabotegravir LA for administration by IM injection.
Placebo
Placebo tablets for cabotegravir are formulated as white to almost white oval-shaped coated tablets to visually match the active cabotegravir tablets. Placebo for cabotegravir injectable suspension is Intralipid® 20%. Intralipid® is a fat emulsion with no pharmacological action. It is a white, milky emulsion, consisting of purified soyabean oil, purified egg phospholipids and anhydrous glycerol. Intralipid® 20% is supplied in infusion bags.
CAPRISA Vulindlela Research Clinic, eMafakatini
CAPRISA eThekwini Research Clinic, Durban
Collaborators (1)
ViiV Healthcare
INDUSTRY
Centre for the AIDS Programme of Research in South Africa
NETWORK